Latest News

Cannabis use is common among patients receiving medications for opioid use disorder and is associated with higher rates of anxiety and other comorbid symptoms.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.

Two studies presented at the World Congress of Nephrology 2026 highlight non-pharmacological strategies that may help preserve kidney function in at-risk populations.

Pharmacists drive acne management by choosing proven OTC ingredients, coaching skin care routines, debunking trends, and knowing when to refer patients to specialists.

The once-weekly Saphnelo Pen offers adult patients with systemic lupus erythematosus a new, at-home alternative to monthly IV infusions, supported by robust phase 3 data.

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.

Large real-world analysis supports potential renal and survival benefits of urate-lowering therapy in patients with chronic kidney disease and hyperuricemia.

Sports Pharmacy Summit unites global experts on anti-doping, supplement safety, and data-driven performance to protect athlete health.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

The treatment's approval was supported by positive evidence from the phase 1/2 CHORD clinical trial.

Emerging data found that initiating low-dose aspirin at giant cell arteritis diagnosis was associated with reduced 1-year major cardiovascular events but an increased risk of major bleeding.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

Lifileucel treats advanced melanoma by harvesting, expanding, and reinfusing a patient's own tumor-fighting immune cells.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

Tracking PDUFA decisions and early planning can lead to safe, rapid access to new medications for patients.

Dupilumab becomes the first biologic approved for children aged 2 to 11 years with uncontrolled chronic spontaneous urticaria, marking a significant expansion in treatment options and pharmacist-led care considerations.

Performing medication reconciliations and assessing for drug interactions are examples of strategies to prevent medication errors.

A postdischarge diabetes follow-up showed me how pharmacists prevent harm by catching omissions, simplifying plans, and using technology to restore patient confidence.

Ecopipam reduces Tourette tic relapse risk by approximately 50% with durable control and no movement-related adverse effects.